首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Transcription factors CP2 and YY1 as prognostic markers in head and neck squamous cell carcinoma: analysis of The Cancer Genome Atlas and a second independent cohort
【24h】

Transcription factors CP2 and YY1 as prognostic markers in head and neck squamous cell carcinoma: analysis of The Cancer Genome Atlas and a second independent cohort

机译:转录因子Cp2和YY1作为头部鳞状细胞癌的预后标志物:分析癌症基因组地图集和第二个独立队列

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Purpose The transcription factors YY1 and CP2 have been associated with tumor promotion and suppression in various cancers. Recently, simultaneous expression of both markers was correlated with negative prognosis in cancer. The aim of this study was to explore the expression of YY1 and CP2 in head and neck squamous cell carcinoma (HNSCC) patients and their association with survival. Methods First, we analyzed mRNA expression and copy number variations (CNVs) of YY1 and CP2 using "The Cancer Genome Atlas" (TCGA) with 510 HNSCC patients. Secondly, protein expression was investigated via immunohistochemistry in 102 patients, who were treated in the Vienna General Hospital, utilizing a tissue microarray. Results The median follow-up was 2.9 years (1.8-4.6) for the TCGA cohort and 10.3 years (6.5-12.8) for the inhouse tissue micro-array (TMA) cohort. The median overall survival of the TCGA cohort was decreased for patients with a high YY1 mRNA expression (4.0 vs. 5.7 years, p = 0.030, corr. p = 0.180) and high YY1-CNV (3.53 vs. 5.4 years, p = 0.0355, corr. p = 0.213). Furthermore, patients with a combined high expression of YY1 and CP2 mRNA showed a worse survival (3.5 vs. 5.4 years, p = 0.003, corr. p = 0.018). The mortality rate of patients with co-expression of YY1 and CP2 mRNA was twice as high compared to patients with low expression of one or both (HR 1.99, 95% CI 1.11-3.58, p = 0.021). Protein expression of nuclear YY1 and CP2 showed no association with disease outcome in our inhouse cohort. Conclusion Our data indicate that simultaneous expression of YY1 and CP2 mRNA is associated with shorter overall survival. Thus, combined high mRNA expression might be a suitable prognostic marker for risk stratification in HNSCC patients. However, since we could not validate this finding at genomic or protein level, we hypothesize that unknown underlying mechanisms which regulate mRNA transcription of YY1 and CP2 are the actual culprits leading to a worse survival.
机译:目的转录因子YY1和CP2在多种癌症中与肿瘤的促进和抑制有关。最近,两种标记物的同时表达与癌症的阴性预后相关。本研究的目的是探讨YY1和CP2在头颈部鳞状细胞癌(HNSCC)患者中的表达及其与生存率的关系。方法首先,我们使用“癌症基因组图谱”(TCGA)对510例HNSCC患者的YY1和CP2的mRNA表达和拷贝数变异(CNVs)进行分析。其次,利用组织微阵列,通过免疫组织化学方法对102名在维也纳总医院接受治疗的患者的蛋白质表达进行了研究。结果TCGA组和TMA组的中位随访时间分别为2.9年(1.8-4.6)和10.3年(6.5-12.8)。对于YY1 mRNA高表达(4.0对5.7年,p=0.030,corr.p=0.180)和YY1-CNV高表达(3.53对5.4年,p=0.0355,corr.p=0.213)的患者,TCGA队列的中位总生存率降低。此外,YY1和CP2 mRNA联合高表达的患者生存率更差(3.5年与5.4年,p=0.003,p=0.018)。YY1和CP2 mRNA共表达患者的死亡率是一种或两种低表达患者的两倍(HR 1.99,95%可信区间1.11-3.58,p=0.021)。在我们的住院队列中,核YY1和CP2的蛋白表达与疾病结局无关。结论我们的数据表明,YY1和CP2 mRNA的同时表达与总生存期较短有关。因此,联合高mRNA表达可能是HNSCC患者风险分层的合适预后标志物。然而,由于我们无法在基因组或蛋白质水平上验证这一发现,我们假设调控YY1和CP2 mRNA转录的未知潜在机制是导致更差生存率的真正罪魁祸首。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号